tbuckley/cabot-search huggingface dataset:
Lower lung function associates with cessation of menstruation: UK Biobank data
Authors: André F.S. Amaral, David P. Strachan, Francisco Gómez Real, Peter G.J. Burney, Deborah L. Jarvis
Journal: European Respiratory Journal (2016)

Little is known about the effect of cessation of menstruation on lung function. The aims of the study were to examine the association of lung function with natural and surgical cessation of menstruation, and assess whether lower lung function is associated with earlier age at cessation of menstruation.The study was performed in 141 076 women from the UK Biobank, who had provided acceptable and reproducible spirometry measurements and information on menstrual status. The associations of lung function (forced vital capacity (FVC), forced expiratory volume in 1 s (FEV1), spirometric restriction (FVC < lower limit of normal (LLN)), airflow obstruction (FEV1/FVC <LLN)) with cessation of menstruation and age at cessation of menstruation were assessed using regression analysis.Women who had natural cessation of menstruation showed a lower FVC (-42 mL; 95% CI -53- -30) and FEV1 (-34 mL; 95% CI -43- -24) and higher risk of spirometric restriction (adjusted odds ratio 1.27; 95% CI 1.18-1.37) than women still menstruating. These associations were stronger in women who had had a hysterectomy and/or oophorectomy. The earlier the natural cessation of menstruation, the lower the lung function. There was no clear association of lung function with age at hysterectomy and/or oophorectomy. Airflow obstruction was not associated with cessation of menstruation.Lower lung function associates with cessation of menstruation, especially if it occurs early in life.
“Real Life” Data on Daas Use among HCV-Patients with Moderate to Severe Chronic Kidney Disease not on Hemodialysis
Authors: A. Moreno, M.J. Vivancos, C. Quereda, M.J. Pérez-Elías, A.D. de Santiago, J.L. Casado, S. Bañón, R. Bárcena, M. García-González, M. Sánchez-Conde, S. del Campo, M.L. Mateos, S. Moreno
Journal: Journal of Hepatology (2016)
A Phase III, Randomized, Double-Blind Trial to Evaluate Efficacy and Safety of Isavuconazole Versus Voriconazole in Patients with Invasive Mold Disease (SECURE): Outcomes in Hematopoietic Stem Cell Transplant Patients with Invasive Aspergillosis
Authors: Werner J Heinz, Oliver A Cornely, Billy Franks, Fei Shi, Nkechi Azie, Johan Maertens
Journal: Blood (2014)
The Level of Residual CLL Objectively Predicts the Outcome of Patients Following FCR-Based Therapy with Sequential Benefits per Log Depletion and Improved Post-Treatment Monitoring
Authors: Andy C Rawstron, Dena Cohen, Ruth Mary De Tute, Lucy McParland, Laura Collett, David Phillips, Anna Chalmers, Abraham Mullasseril Varghese, Talha Munir, Walter M Gregory, Peter Hillmen
Journal: Blood (2015)
Soluble CD163, a Marker of Macrophage Activation, is Increased in Early Allograft Dysfunction after Liver Transplantation
Authors: K.L. Thomsen, R. Jalan, F.P. Robertson, P. Holland-Fischer, B.R. Davidson, R. Mookerjee, H.J. Møller, H. Grønbæk
Journal: Journal of Hepatology (2016)
Treatment of Patients with Hepatitis C Virus (HCV) Genotype 3 Infection in the Era of Direct Acting Antivirals (DAA): Data from the German Hepatitis C-Registry (DHC-R)
Authors: M. Cornberg, P. Buggisch, A. Schober, G. Schmutz, K.H.W. Böker, R. Link, S. Christensen, K.-G. Büscher, H. Pfeiffer-Vornkahl, M.P. Manns, C. Sarrazin, D. Hüppe, T. Berg, C. Niederau
Journal: Journal of Hepatology (2016)
Highlights in Central Nervous System Tumors
Authors: Anne Hertenstein, Michael Platten, Wolfgang Wick
Journal: JAMA Oncology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Evaluation of Immune Profile in Patients with Multiple Myeloma Using Cytof Technology
Authors: Jana Jakubikova, Efstathios Kastritis, Danka Cholujova, Teru Hideshima, Ludmila M Flores, Merav Leiba, Jacob P. Laubach, Nikhil C. Munshi, Paul Richardson, David M Dorfman, Kenneth C. Anderson
Journal: Blood (2014)
Expanded Access Program Of Ponatinib (AP24534) For Patients (Pts) With Refractory Chronic Myeloid Leukemia (CML) Or Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)
Authors: Ghayathri Jeyakumar, Hagop M. Kantarjian, Kendra L. Sweet, Cecilia Y Arana Yi, Nitin Jain, Elias Jabbour, Alfonso Quintas-Cardama, Susan O'Brien, Brenda Walker, Sherry R. Pierce, Tapan M. Kadia, Farhad Ravandi, Javier Pinilla, Jorge E. Cortes
Journal: Blood (2013)
Association of plasma EGFR T790M ctDNA status with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance.
Authors: Di Zheng, Xin Ye, Meizhuo Zhang, Yun Sun, Jiying Wang, Jian Ni, Haiping Zhang, Ling Zhang, Jie Luo, Jie Zhang, Liang Tang, Bo Su, Gang Chen, Guanshan Zhu, Yi Gu, Jianfang Xu
Journal: Journal of Clinical Oncology (2015)

8080 Background: EGFR T790M mutation occurs in around half of non-small cell lung cancer (NSCLC) patients with acquired EGFR-TKI (TKI) resistance, based on tumor tissue re-biopsies using an invasive clinical procedure. Here, we evaluated the feasibility of detecting T790M mutation in circulating tumor DNA (ctDNA), using serial plasma samples from NSCLC patients receiving TKI to further investigate its association with clinical outcome. Methods: Patients with advanced or recurrent NSCLC receiving TKI were enrolled consecutively and blood samples were taken every 2 months, including post-TKI failure. Upon TKI failure, patients were given continued TKI alone or TKI plus chemotherapy at the discretion of the physician. EGFR ctDNA in plasma was measured using Droplet Digital PCR (ddPCR) assay. Overall survival (OS) of starting from initial TKI treatment was analyzed according to the T790M ctDNA status detected in plasma. Results: Among 318 patients, 117 who acquired TKI resistance (with 391 plasma samples) were eligible for the analysis. T790M ctDNA was detected in the plasma of 55/117 (47%) patients. Almost half of the T790M ctDNA positive patients were identified at a median time of 2.2 months prior to clinical progressive disease (PD). Furthermore, T790M ctDNA positive patients had significantly shorter OS compared to negative patients (median OS: 808 versus 1083 days, P = 0.0418). Conclusions: Our study demonstrates the feasibility of monitoring EGFR mutation dynamics in serial plasma samples from NSCLC patients receiving TKI therapy. T790M ctDNA can be detected in plasma before and after PD and represents a potential poor prognostic factor.
The management of acne vulgaris in primary care: a cohort study of consulting and prescribing patterns using the Clinical Practice Research Datalink
Authors: N.A. Francis, K. Entwistle, M. Santer, A.M. Layton, E.A. Eady, C.C. Butler
Journal: British Journal of Dermatology (2016)

Effective management of acne vulgaris in primary care involves support (usually provided over a number of consultations) and prescription of effective treatments. However, consulting and prescribing patterns for acne in primary care are not well described.To describe the rate of primary-care consultations and follow-up consultations; prescribing patterns, including overall use of acne-related medications (ARMs); and initial and follow-up prescription for acne vulgaris in the U.K.U.K. primary-care acne consultations and prescriptions for ARMs were identified in the Clinical Practice Research Datalink. Annual consultation rates (between 2004 and 2013) by age and sex, new consultations and consultations in the subsequent year were calculated, along with prescribing trends - during a new consultation and over the subsequent 90 days and year - using the number of registered patients as the denominator.Two-thirds (66·1%) of patients who had a new acne consultation had no further acne consultations in the subsequent year. Overall 26·7%, 24·9%, and 23·6% and 2·8% of patients were prescribed no ARM, an oral antibiotic, a topical antibiotic or an oral plus topical antibiotic, respectively, during a new acne consultation. In total 60·1% and 38·6% of patients prescribed an ARM received no further ARM prescriptions in the following 90 days and 1 year, respectively, despite most prescriptions being for 2 months or less. Prescribing rates for lymecycline and topical combined clindamycin and benzoyl peroxide increased substantially between 2004 and 2013. There were no important changes in consultation rates between 2004 and 2013.These data suggest that patients with acne are receiving a suboptimal initial choice of ARMs, longitudinal care and prescribing.
Surveillance de la grippe dans le Nord-Ouest de l'Angleterre en 2001-02
Authors: C M Regan, W Sopwith, M Ashton, Q Syed, M Painter, K Mutton, K Paver
Journal: Eurosurveillance (2002)

Un reseau local de surveillance sentinelle a ete instaure dans la region Nord-Ouest de l’Angleterre pour controler la grippe. Durant l’hiver 2001-02, les taux de consultations pour la grippe ou un syndrome grippal ont ete faibles, mais le reseau a pu reveler des variations sous-regionales dans la survenue des pics d’activite grippale, et dans l’infection des divers groupes d’âge. Ceci suggere que le reseau peut contribuer a ameliorer la planification des besoins des services de sante du Nord-Ouest de l’Angleterre pour la saison d’hiver.
Presepsin (Soluble CD14 Subtype) Levels in Cirrhotic Patients with Compensated or Decompensated Liver Disease with or without Portal Hypertension Related Bleeding
Authors: I.S. Elefsiniotis, S. Tsakiris, E. Evangelidou, G. Barla, A. Tasovasili, I. Stathopoulou, E. Giannakoulopoulou, D. Vrachatis, C. Mavrogiannis
Journal: Journal of Hepatology (2016)
The Outcome of Children with T-Cell Acute Lymphoblastic Leukemia: A Single Institution Experience.
Authors: Ali Al-Ahmari, Asim F. Belgaumi, Abdelmuniem Al-Dalee, Mohammed Al-Mahr, Abdulrahman Al-Musa, Mahasen Saleh, Amal S. Al-Seraihy, Ashraf R. Khairy, Hassan El-Solh
Journal: Blood (2006)
P1035 : ELF test is a reliable non invasive test for fibrosis in NAFLD subjects
Authors: L. Miele, T. De Michele, M.A. Isgrò, G. Marrone, C. Cefalo, M. Biolato, G.L Rapaccini, A. Gasbarrini, C. Zuppi, A. Grieco
Journal: Journal of Hepatology (2015)
Poor response to initial reduction therapy (COP) and combined bone marrow and CNS disease are poor prognostic factors in children with advanced (BM +/- CNS) B-NHL treated on the international study FAB/LMB96.
Authors: Cairo, M Gerrard, R Sposto, A Auperin, R Pinkerton, J Michon, S Perkins, M Raphael, K McCarthy, C Weston, C Patte
Journal: Blood (2003)
Condylomata acuminata of HIV-positive men may harbour focal areas of dysplasia: relevant implications for the management of human papillomavirus-induced disease in high-risk patients
Authors: A. Kreuter, U. Wieland
Journal: British Journal of Dermatology (2016)

Linked Article: Siegenbeek van Heukelom et al. Br J Dermatol 2016; 175:735–743.
Transient potential channel A1 and mast cell activation in bronchial hyperreactivity caused by hypochlorite and OVA in mice
Authors: Valérie Hox, Jeroen Vanoirbeek, Yeranddy Aguiar Alpizar, S Voedisch, Sonja Bobic, Ina Callebaut, Vanessa De Vooght, A Sharify, Laura Van Gerven, Jan Ceuppens, Annick de Vries, A Braun, Peter Hoet, K Talavera, Benoit Nemery, Peter Hellings
Journal: Allergy (2012)
A Genotype-Specific Baseline Score to Predict Response at 48 Weeks Post-Treatment to Peginterferon Alfa-2a in Patients with HBeAg-Negative Chronic Hepatitis B
Authors: P. Lampertico, D. Messinger, M. Cornberg, M. Brunetto, J. Petersen, P. Kennedy, T. Asselah, V. Rothe, A. Caputo, G. Bakalos, V. Pavlovic, G.V. Papatheodoridis
Journal: Journal of Hepatology (2016)
Final Results of the Pyramid 1 Study, a Phase 3 Registrational Trial of Ravidasvir (PPI-668) and Sofosbuvir in HCV Genotype-4 Patients: High Rates of Sustained Viral Clearance in Cirrhotic and Non-Cirrhotic Patients
Authors: G. Esmat, M. El Raziky, A. Gomaa, T. Elbaz, M. Abouelkhair, A. Sabry, H. Gamel, E. Deen, M. Ashour, M. Abdel-Hamid, O. Nada, S. Helmy, H. Abdel-Maguid, R. Colonno, N. Brown, E. Ruby, P. Vig, I. Waked
Journal: Journal of Hepatology (2016)
Steady-State Pharmacokinetics of Sofosbuvir and Velpatasvir in HCV-Infected Subjects without Cirrhosis, with Compensated Cirrhosis, or with Decompensated Cirrhosis in the Phase 3 Astral Studies
Authors: E. Mogalian, Di An, Y. Zhu, Y. Maruca, C. Casey, J. McNally, J. Ling, A. Mathias
Journal: Journal of Hepatology (2016)
Direct Observed Therapy of Chronic Hepatitis C with Interferon-Free All-Oral Regimens at a Low-Threshold Drug Treatment Facility – a New Concept for Treatment of Patients with Borderline Compliance Receiving Opioid Substitution Therapy
Authors: S. Moser, A. Schütz, K. Marchart, S. Ambrosch, A. Karpi, E. Gutic, H. Haltmayer, M. Gschwantler
Journal: Journal of Hepatology (2016)
The National Lung Cancer Audit in the United Kingdom: Results after 4 years.
Authors: P. Beckett, I. Woolhouse, R. Stanley, M. D. Peake
Journal: Journal of Clinical Oncology (2010)

6123 Background: The National Lung Cancer Audit is run jointly by the Royal College of Physicians and The Information Centre for health and social care. Its development was driven by the realization that lung cancer outcomes vary widely across Great Britain and are poor compared to other western countries. The aim is to record outcomes in lung cancer on a large scale and through case-mix adjustment, start to explain the wide variations noted and facilitate service improvement. Methods: All hospitals are invited to participate in this audit, which is not mandatory. The dataset includes over 100 fields covering demographics, referral, investigations, diagnosis, treatment and survival and includes age, sex, postcode, stage, and performance status allowing case-mix adjustment to be carried out. Incident cases of lung cancer and mesothelioma are uploaded to a central database and cases are analysed on a “date first seen” basis. Although Scotland submits a subset of data, this abstract presents results for England and Wales only. Results: There has been a yearly increase in participation and by June 2008, all networks in Great Britain were contributing to the audit. In 2008, there were 28,389 records submitted from England and Wales, representing 85% of the annual incidence and 94% of those presenting to secondary care. The table below shows the quality of the data submitted as well as process and outcome measures. Conclusions: These results highlight the considerable achievement of the National Lung Cancer Audit in collecting data and suggest that care for lung cancer patients is slowly improving. However, wide variations in outcomes persist between organisations. The quality of the data now allows further analysis to determine whether such variations can be explained by case-mix. Such information will be a powerful lever for reducing variation and further improving quality of care and outcomes. Data completeness 2005 (%) 2006 (%) 2007 (%) 2008 (%) Histology 79 78 82 90 PS 66 77 80 87 Staging 51 55 70 77 Process and outcomes 2005 (%) 2006 (%) 2007 (%) 2008 (%) Confirmed histological diagnosis 68 66 65 67 Discussed at MDT? 79 84 87 89 Any anticancer treatment? 45 50 52 54 Overall surgical resection rate 9 9.4 10.3 11.2 NSCLC resection rate 13.8 14.3 15.2 16 SCLC chemotherapy rate 58 62 65 63 No significant financial relationships to disclose.
Next steps for IBM Watson Oncology: Scalability to additional malignancies.
Authors: Andrew S. Epstein, Marjorie Glass Zauderer, Ayca Gucalp, Andrew David Seidman, Aryeh Caroline, Julia Fu, Jeffrey Keesing, Franny Hsiao, Mark Megerian, Thomas Eggebraaten, Robert DeLima, Marie Setnes, Peter Bach, Mark G. Kris
Journal: Journal of Clinical Oncology (2014)

6618 Background: We reported on the development of IBM Watson Oncology, a cognitive computing system designed to inform clinical decision making. The initial prototype demonstrated results (Bach, Proc ASCO 2013) in lung cancers, including the complexities of natural language processing. Here, we report the experience scaling the tool to additional cancers using an alternative method of attribute collection. Methods: Memorial Sloan Kettering and IBM's continued collaboration now includes the creation of electronic decision support prototypes for colon, rectal, bladder, pancreatic, kidney, ovarian, cervical and endometrial cancers. To date, each prototype has been created with IBM Watson and trained by Memorial Sloan Kettering physicians by identifying key attributes common to all cancers (e.g., stage, age) and specific to individual cancers (e.g., high risk features for stage II colon cancer), manually entering attribute and candidate treatment answer combinations, and ranking treatments as preferred, acceptable, or not recommended. Precision, defined as [(correct preferred treatments)/(correct preferred treatments + false positives (incorrect preferred treatments) + false negatives (missing preferred treatments))], was measured for each prototype. Results: To date, each cancer prototype has been created with dozens of training cases and candidate treatment answers. Average precision, retesting with the same training data, has improved from 5% to nearly 100% depending on the cancer type. Table 1 is provided as a descriptive summary and not a statement of statistical significance. Conclusions: IBM Watson Oncology's training is scalable to additional cancers and today covers the majority of solid tumors, including breast and lung. Future steps include using additional machine learning features and training cases to improve precision, testing using blind cases, and using natural language processing to automatically extract clinical attributes from electronic medical records. Average precision (%) by disease site. First run Middle run Latest run Colon 68 81 98 Rectal 61 88 96 Bladder 24 75 91 Pancreatic 5 91 94 Kidney 12 87 91 Ovarian 41 97 95 Cervical 6 100 100 Endometrial 12 83 89
Change in NIH Skin Score 0–3 Correlates with Provider- and Patient-Reported Skin Changes and Overall Survival: Results From the Chronic Gvhd Consortium
Authors: David Jacobsohn, Stephanie J. Lee, Brenda Kurland, Corey S. Cutler, Joseph Pidala, Paul A. Carpenter, Shawn Chai, Sally Arai, Mukta Arora, Jeanne Palmer, Paul J. Martin, Steven Z. Pavletic, Mary E.D. Flowers
Journal: Blood (2011)
P0862 : First real clinical practice data on sofosbuvir, simeprevir and daclatasvir with HCV-chronically infected patients in Spain: The HepatiC registry experience
Authors: C. Fernández-Carrillo, J.M. Pascasio, S. Lens, C. Vinaixa, E. Fraga, M. Buti, M. Romero-Gómez, J. García-Samaniego, J. Crespo, D. Rincón, J.L. Calleja
Journal: Journal of Hepatology (2015)
MCJ/DnaJC15, the Mitochondrial Foe in Liver Injury
Authors: L.B. Torres, P. Iruzubieta, D. Taibo, T. Cardoso, N. Navasa, D.F. Ramos, M.V. Rey, V.G. de Juan, P.F. Tussy, I.Z. Franco, M.I.H. Alvarez, R. Andrade, I. Medina, M.J. Monte, J.J.G. Marín, J. Crespo, A. Zorzano, J.M. Mato, J. Anguita, M. Rincon, M.L.M. Chantar
Journal: Journal of Hepatology (2016)
A drug interaction study between dextromethorphan and panobinostat (LBH589), an orally active deacetylase inhibitor, in patients with advanced cancer.
Authors: R. Feld, M. M. Woo, F. A. Shepherd, N. B. Leighl, R. Elshtein, T. Hengelage, S. Hirawat
Journal: Journal of Clinical Oncology (2010)

e13089 Background: Panobinostat (PAN; LBH589) has been found to inhibit CYP2D6 in vitro. It was hypothesized that PAN may inhibit the metabolic clearance of comedications metabolized by CYP2D6 in patients (pts). A crossover study was designed to assess the inhibitory effect of PAN on the disposition of dextromethorphan (DM, a sensitive CYP2D6 substrate) in pts with advanced cancer. Methods: Pts with advanced solid tumors with adequate organ function and ECOG PS ≤2 received single-agent DM 60 mg po on Day (D) 1 and PAN at 20 mg/day po on Days 3, 5, and 8. On D 8, the second DM dose was administered 1 hr after PAN dose. Prior to drug administration, genotyping analysis of CYP2D6 gene was performed using AmpliChipCYP450 in consenting pts. Serial plasma samples were collected for DM pharmacokinetic (PK) evaluations on D 1 and 8. Plasma concentrations of DM and its metabolite dextromethorphan (DX) were measured by LC-MS-MS. PK parameters were estimated by using non-compartmental analysis. Results: 17 pts were enrolled with median age 67 years (range 47–74). 14 pts were evaluable for DM PK on D 1 and 8, of whom 13 pts were classified as extensive or intermediate metabolizers (EM or IM) of CYP2D6 by genotyping method, and 1 pt was classified as EM by metabolic ratio DM/DX. DM PK parameters are expressed as either mean (CV%), median (range) or ratio (see Table). Coadministration of PAN and DM increased DM Cmax and AUC by 1.8- and 1.6-fold, respectively, but with no change in Tmax. Conclusions: The observed increase in DM AUC upon coadministration with PAN in nonpoor CYP2D6 metabolizers is most probably a result of CYP2D6 inhibition by PAN. However, the less than 2-fold increase in DM exposure suggests PAN has a weak CYP2D6 inhibition potential on a sensitive CYP2D6 substrate. It is concluded that clinically relevant interactions between PAN and CYP2D6 substrates may occur only in medications that are sensitive CYP2D6 substrates, which also have a narrow therapeutic index. D 1 DM alone D 8 PAN + DM N 14 14 Tmax (hr) 1 (0.5–4) 1 (0.5–6) Cmax (ng/mL) 13 (151%) 17 (121%) AUC0-inf (ng*hr/mL) 188 (170%) 157 (138%) Comparison geometric mean ratio with (90% CI) - Combo/PAN Cmax ratio - 1.8 (1.4–2.3) AUC ratio 1.6 (1.2–2.3) Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Novartis Novartis Novartis
PET imaging of hypoxia with the new tracer 18F-HX4: A phase 1 trial
Authors: Judith van Loon, Dirk De Ruysscher, Marco Janssen, Michel Oellers, Anne-Marie Dingemans, Monique Hochstenbag, Roy Lalisang, Boudewijin Brans, Bert Windhorst, Guus van Dongen, James Zhang, Philippe Lambin
Journal: Journal of Thoracic Oncology (2009)